Truist Securities Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained a Buy rating on Amneal Pharmaceuticals and raised the price target from $10 to $12, indicating confidence in the company's future performance.
October 02, 2024 | 1:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities has maintained a Buy rating on Amneal Pharmaceuticals and increased the price target from $10 to $12, suggesting a positive outlook for the company's stock.
The increase in the price target from $10 to $12 by Truist Securities indicates a positive outlook for Amneal Pharmaceuticals. This suggests that the analyst expects the company's stock to perform well, which could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100